Prognosis and Advanced Care Options
At a Glance
CPFE prognosis varies widely and is not predicted by older survival statistics alone. Doctors consider pulmonary hypertension, lung cancer, gas transfer, oxygen needs, symptoms, and imaging. Transplant may help people with advanced CPFE, while palliative care supports comfort at any stage.
Thinking about the future with Combined Pulmonary Fibrosis and Emphysema (CPFE) can be daunting. Because CPFE involves two different lung conditions, its path is not the same for everyone. Your medical team uses specialized tools to understand your unique risk and help you make decisions about advanced treatments like lung transplantation or palliative care.
Understanding Your Prognosis
It is important to know that “prognosis” is an estimate based on groups of people, not a certain prediction for you. When researching CPFE, you may encounter older survival statistics (such as median survival ranges of roughly 2 to 8.5 years) [1][2]. It is vital to understand that a “median” is a midpoint from older, historical studies based on diverse groups of patients; it is not a prediction or a countdown for you. The definitions of CPFE, available treatments, and patient populations have changed substantially over time.
Your individual outlook depends heavily on several “risk markers” that your doctor monitors closely:
- Pulmonary Hypertension (PH): Having high blood pressure in the lung arteries is one of the most significant factors that can impact survival in CPFE [3][4].
- Lung Cancer: Because CPFE increases the risk of lung cancer, the presence of a tumor can significantly change the treatment plan and outlook [5][6].
- Diffusion Capacity (DLCO): How well your lungs move gas (your DLCO score), along with your oxygen needs during exertion, are often a better predictor of your health than your total lung volume [5][7].
The Composite Physiologic Index (CPI)
Standard breathing tests (spirometry) can be misleading in CPFE because emphysema and fibrosis “mask” each other. To assist with this, some doctors calculate an optional score called the Composite Physiologic Index (CPI) [8].
The CPI combines several test results (DLCO, FVC, and FEV1) into a single number [9].
- What the score means: A higher CPI score generally indicates a more advanced level of lung scarring [8].
- Tracking change: Your doctor may look at how your CPI changes over time to estimate progression. However, the CPI is an optional clinician tool, not an absolute trigger. Medical decisions—such as referring for a transplant—are based on your whole clinical picture, including symptoms, oxygen needs, and imaging, not just hitting a specific CPI cutoff [10][5].
Lung Transplantation
For patients with advanced CPFE, a lung transplant can offer a chance at a longer and more active life.
- Outcomes: Select studies from specialized centers have shown that people with CPFE who receive a transplant have survival rates comparable to those with other forms of lung fibrosis, with about 74% to 79% of patients in those cohorts reaching the 5-year mark after surgery [11][12]. However, outcomes depend heavily on the specific center, your comorbidities, and whether you receive single or bilateral lungs.
- Evaluation: The process for being “listed” for a transplant is complex. It involves testing your heart, your nutrition, and your support system at home [11]. Because evaluation takes time, early referral to a transplant center is highly encouraged if your specialist sees concerning progression.
- Risks: While the survival rates are encouraging, CPFE transplant recipients may have a slightly higher risk of certain early complications, such as primary graft dysfunction (where the new lungs take longer to start working) [12].
The Role of Palliative Care
Palliative care is often misunderstood as being synonymous with hospice, which is only for the very end of life. In reality, palliative care is concurrent supportive care that you can receive at any stage of CPFE, alongside your disease-directed treatments [13].
- Symptom Management: The main goal of palliative care in CPFE is to treat “refractory dyspnea”—severe shortness of breath that doesn’t fully go away with inhalers or oxygen alone [13].
- Quality of Life: Palliative specialists can help manage the anxiety, fatigue, and “air hunger” that often come with advanced lung disease, ensuring you can focus on the activities and people that matter most to you [13].
Common questions in this guide
What factors affect the outlook for someone with CPFE?
What is the CPI score used for in CPFE?
When should I ask about a lung transplant for CPFE?
How successful is lung transplantation for people with CPFE?
Can palliative care help with CPFE before hospice?
What should be included in advance care planning for CPFE?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Combined pulmonary fibrosis-emphysema syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my current health, oxygen needs, and disease progression, am I a candidate for a lung transplant evaluation?
- 2.Is there a palliative care team at this hospital that can help me manage my shortness of breath while I continue my other treatments?
- 3.How does the presence of pulmonary hypertension or my specific fibrosis pattern impact my long-term outlook?
- 4.If my condition worsens suddenly, what is our action plan for emergency care or hospital admission?
References
References (13)
- 1
Combined pulmonary fibrosis and emphysema: The many aspects of a cohabitation contract.
Papaioannou AI, Kostikas K, Manali ED, et al.
Respiratory medicine 2016; (117()):14-26.
PMID: 27492509 - 2
Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema.
Collum SD, Molina JG, Hanmandlu A, et al.
Disease models & mechanisms 2019; (12(5)) doi:10.1242/dmm.038711.
PMID: 31036697 - 3
An increased risk of pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema: a meta-analysis.
Ni H, Wei Y, Yang L, Wang Q
BMC pulmonary medicine 2023; (23(1)):221 doi:10.1186/s12890-023-02425-4.
PMID: 37344866 - 4
Combined pulmonary fibrosis and emphysema as a clinicoradiologic entity: Characterization of presenting lung fibrosis and implications for survival.
Alsumrain M, De Giacomi F, Nasim F, et al.
Respiratory medicine 2019; (146()):106-112 doi:10.1016/j.rmed.2018.12.003.
PMID: 30665507 - 5
Prognostic factors in combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis.
Xu L, Zang D, Yan R, et al.
Journal of thoracic disease 2026; (18(2)):92 doi:10.21037/jtd-2025-aw-2054.
PMID: 41816468 - 6
Radiologic Pattern of Fibrosis in Combined Pulmonary Fibrosis and Emphysema: Impact on Disease Trajectories and Prognostic Outcomes.
Kim MS, Choe J, Hwang HJ, et al.
Radiology 2026; (318(2)):e251686 doi:10.1148/radiol.251686.
PMID: 41733469 - 7
Long-term follow-up results of patients with combined pulmonary fibrosis and emphysema: A single-center experience.
Calis AG, Uzer F, Gurbuz AF, et al.
Respiratory medicine 2026; (255()):108780 doi:10.1016/j.rmed.2026.108780.
PMID: 41856387 - 8
Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study.
Lee SH, Park JS, Kim SY, et al.
Scientific reports 2018; (8(1)):4784 doi:10.1038/s41598-018-23073-3.
PMID: 29555917 - 9
Prognostic value of a composite physiologic index developed by adding bronchial and hyperlucent volumes quantified via artificial intelligence technology.
Uyama M, Handa T, Uozumi R, et al.
Respiratory research 2024; (25(1)):442 doi:10.1186/s12931-024-03075-8.
PMID: 39719582 - 10
Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis.
Zhang L, Zhang C, Dong F, et al.
BMC pulmonary medicine 2016; (16(1)):137 doi:10.1186/s12890-016-0300-7.
PMID: 27809901 - 11
Outcomes of Lung Transplantation in Patients With Combined Pulmonary Fibrosis and Emphysema: A Single-Center Experience.
Narula T, Martin AK, Asif AA, et al.
Transplantation proceedings 2023; (55(2)):449-455 doi:10.1016/j.transproceed.2023.01.010.
PMID: 36849338 - 12
Clinical Features and Outcomes of Combined Pulmonary Fibrosis and Emphysema After Lung Transplantation.
Takahashi T, Terada Y, Pasque MK, et al.
Chest 2021; (160(5)):1743-1750 doi:10.1016/j.chest.2021.06.036.
PMID: 34186034 - 13
Combined Pulmonary Fibrosis and Emphysema and Digital Clubbing.
Rasul TF, Bergholz DR, Rovinski R, et al.
Cureus 2022; (14(4)):e24231 doi:10.7759/cureus.24231.
PMID: 35602819
This page is for informational purposes only and does not replace professional medical advice. Discuss your CPFE prognosis, transplant evaluation, palliative care, and emergency plan with your pulmonary care team.